Search
Pradofloxacin
go.drugbank.com/drugs/DB11453ExperimentalVet approvedIt was approved by the European Commission in April 2011 for bacterial infections in dogs and cats.
Inarigivir
go.drugbank.com/drugs/DB15062InvestigationalInarigivir is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of Inarigivir (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis
Dilpacimab
go.drugbank.com/drugs/DB16140InvestigationalDilpacimab is under investigation in clinical trial NCT03368859 (A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine
Phthalocyanine
go.drugbank.com/drugs/DB12983InvestigationalPhthalocyanine is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage
Tizaterkib
go.drugbank.com/drugs/DB21296InvestigationalTizaterkib is under investigation in clinical trial NCT04305249 (Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological … The usage of the INN stem '-terkib' in the name indicates that Tizaterkib is a extracellular signal-regulated kinase (ERK) inhibitor.
Tofimilast
go.drugbank.com/drugs/DB11681InvestigationalTofimilast has been used in trials studying the treatment of Asthma and Pulmonary Disease, Chronic Obstructive.
Tofogliflozin
go.drugbank.com/drugs/DB11824InvestigationalTofogliflozin has been used in trials studying the treatment and prevention of Diabetes Mellitus Type 2.
IQP-0528
go.drugbank.com/drugs/DB14888InvestigationalIQP-0528 is under investigation in clinical trial NCT03082690 (ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study).
Rivenprost
go.drugbank.com/drugs/DB16315InvestigationalRivenprost is under investigation in clinical trial NCT00296556 (Therapeutic Study of ONO-4819CD for Ulcerative Colitis).
DYN-101
go.drugbank.com/drugs/DB17921InvestigationalDYN-101 is an antisense product candidate designed to reduce the expression of dynamin 2 protein.